item management s discussion and analysis of financial condition and results of operation a the company introduction the company has been developing over oral controlled release pharmaceutical products which are at the varying stages of the development process and testing 
elite labs has also conducted several research and development projects on behalf of several large pharmaceuticals companies 
these activities have generated only limited revenue for elite labs to date 
the company has established a manufacturing facility in northvale  nj which is both fda and dea registered 
this facility will allow the company to make batches in sizes sufficient to file for fda approval 
in october  elite entered into a joint development and operating agreement with elan corporation  plc  and elan international services  ltd 
together elan to develop products using drug delivery technologies and expertise of both companies 
this joint venture  elite research  ltd 
erl  a bermuda corporation  is initially owned by elite and by elan 
erl will fund its research through capital contributions from its partners based on the partners ownership percentage 
erl will subcontract research and development efforts to elite  elan and others 
the in vivo pilot bioavailability has been completed on the first product formulated by elite labs 
elite has begun to develop formulations for the two additional products 
in june  the company entered into two separate and distinct development and license agreements with another us pharmaceutical company to develop two products in exchange for development fees  certain payments  royalties and manufacturing rights 
elite has undertaken formulation development for these two products and has earned the development fees paid to date 
in september  elite received approval of its application to sell  in new jersey net operating tax losses under the new jersey economic development agency s technology business tax certificate program 
the company received  of proceeds from this sale 
in november  elite received approval of its application to sell an additional  in new jersey net operating tax losses under the new jersey economic development agency s technology business tax certificate program 
the company expects to receive   was received during the quarter ending december  in october  the company authorized the purchase of up to  shares of its common stock in the open market at the then prevailing market price on or before march  there has been no repurchases of any common stock during this period 
the company plans to focus its efforts on the following areas i to receive fda approval for one or all of the oral controlled release pharmaceutical products already developed  either directly or through other companies  ii to commercially exploit these drugs either by licensure and the collection of royalties  or through the manufacturing of tablets and capsules using the formulations developed by the company  and iii to continue the development of new products and the expansion of its licensing agreements with other pharmaceutical companies including contract research and development projects  joint ventures and other collaborations 
the company has been issued three patents to date and has filed for two more patents 
one of the patents has been assigned to celgene who has now licensed it to novartis 
critical accounting policies and estimates management s discussion addresses the company s consolidated financial statements  which have been prepared in accordance with accounting principles generally accepted in the united states of america 
the preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities  the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period 
on an ongoing basis  management evaluates its estimates and judgment  including those related to bad debts  intangible assets  income taxes  workers compensation  and contingencies and litigation 
management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances  the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources 
actual results may differ from these estimates under different assumptions or conditions 
management believes the following critical accounting policies  among others  affect its more significant judgments and estimates used in the preparation of its consolidated financial statements 
the company s most critical accounting policies include the recognition of revenue upon completion of certain phases of projects under research and development contracts 
the company also assesses a need for an allowance for doubtful accounts and determines a need for valuation allowance to reduce its deferred tax assets to the amount that it believes is more likely than not to be realized 
the company assesses the recoverability of long lived assets and intangible assets whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable 
the company assesses its exposure to current commitments and contingencies 
it should be noted that actual results may differ from these estimates under different assumptions or conditions 
rules of consolidated operations year ended march  vs 
year ended march  elite s revenues for the year ended march  were  an increase of  or approximately  over the comparable period of the prior year 
net revenues include research and development fees totaling  of which  was earned in conjunction with two separate and distinct development and licensing agreements with another pharmaceutical company  product formulation fees of  earned in conjunction with the company s joint venture in erl and  of consulting and testing fees 
comparable prior period revenues were   and  respectively  for the above components that comprise total revenues 
general and administrative expenses for the year ended march  were  a decrease of  or approximately  from the comparable period of the prior year 
the decrease in general and administrative expenses was substantially due to a decrease in consulting fees 
general and administrative expenses expressed as a percentage of revenues were approximately for the year ended march  as compared to for the comparable period of the prior year 
research and development costs for the year ended march  were  an increase of  or approximately  from the comparable period of the prior year 
research and development costs have increased as the company has undertaken certain biostudies that were not undertaken in the prior year 
research and development expenses expressed  as a percentage of revenues were and  respectively  for the years ended march  and march  elite s net loss for the year ended march  was  as compared to  for the comparable period of the prior year 
the decrease in the net loss was primarily due to the decrease of  in equity loss of its owned joint venture  which included a one time charge of  in the prior comparable period for the company s share of the  payment to elan for a technology license 
year ended march  vs 
year ended march  elite s revenues for the year ended march  were  an increase of  or approximately  over the comparable period of the prior year 
net revenues consisted of product formulation fees of  earned in conjunction with the company s joint venture in erl and  of consulting and test fees compared with  of consulting and test fees for the comparable period of the prior year 
general and administrative expenses for the year ended march  were  a decrease of  or approximately from the comparable period of the prior year 
the decrease in general and administrative expenses was substantially due to a decrease in consulting fees 
general and administrative expenses expressed as a percentage of revenues were approximately for the year ended march  as compared to for the comparable period of the prior year 
research and development costs for the year ended march   were  a decrease of  or approximately  from the comparable period of the prior year 
research and development costs have declined  as the company has not undertaken the kind of biostudies that were undertaken in the prior year 
elite s net loss for year ended march  was  as compared to  for the comparable period of the prior year 
the increase in the net loss was primarily due to  of equity in the loss of its owned joint venture  erl  partially offset by the  of income recognized in connection with the sale of new jersey net operating tax losses 
the  equity in the loss of erl includes a one time charge of  for the company s share of the  payment to elan for a technology license fee 
liquidity and capital resources the company s working capital total current assets less total current liabilities  which was  as of march  decreased to  as of march  the company s net loss from operations  increases in restricted cash  and purchases and deposits on property and equipment was offset by proceeds from the issuance of common stock and warrants and the bank note 
for the year ended march   the company experienced negative cash flows from operations of  primarily due to the company s net loss from operations of  for the year ended march   the company experienced negative cash flows from operations of  primarily due to the company s net loss from operations of  b elite research  ltd 
elite research  ltd 
erl  a bermuda corporation  was incorporated in october erl  which is initially owned by elite pharmaceuticals  inc and by elan corporation  plc 
and elan international services  ltd 
 was organized to develop products using drug delivery technologies and expertise of both companies 
erl will fund its research through capital contributions based on the partners ownership percentages and will subcontract research development efforts to elite  elan  and others 
results of operations year ended march  vs 
year ended march  to date  there have been no revenues recognized by elite research  ltd 
research and development costs for the year ended march  of  were incurred on contracts with epi 
these costs increased by  or approximately from the comparable period of the prior year 
this is the result of erl incurring costs associated with the later stages of formulation  development and testing of three products in the current period compared to one product in the previous comparable period 
general and administrative costs for the year ended march  were  compared to for the comparable period of the prior year 
this was the result of administrative expenses and the payment of a franchise tax imposed by bermuda 
licensing fees decreased in the current year 
in the year ended march   erl incurred a one time  payment to elan for a technology license 
liquidity and capital resources the working capital total current assets less total current liabilities of erl  which was  as of march  decreased to  as of march  capital contributions for research and development activities were more than offset by erl s net loss from operations 
in april  additional contributions were funded by elite and elan in the amount of  and  respectively 
item a 
quantitative and qualitative disclosures about market risk the company does not invest in or own any market risk sensitive instruments entered into for trading purposes or for purposes other than trading purposes 
all loans to the company have been made at fixed interest rates  accordingly  the market risk to the company prior to maturity is very minimal 

